RxDoctor Payments DataLook up a doctor →

James Branch, MD

Ophthalmology · Mocksville, NCNPI 1538147061

Payments from drug & device makers

$938,130in general payments, 2019–2025

Across 234 payments — averaging $4009.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$715K
  • Padagis US LLC$140K
  • Alcon Research LLC$64K
  • Perrigo Company PLC$20K
  • Amgen$151
  • Kala Pharmaceuticals, Inc.$98
  • plus $219 from 6 others
$341,154in research payments, 2019–2025

Across 80 payments — averaging $4264.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$299K
  • Shire North American Group Inc$41K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K

What the payments were for

  • Travel & lodging$1,04138%
  • Food & beverage$1,58058%
  • Education$984%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$938,130 in reported general payments places this provider in the 95th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$37,818
Medicare patients
148
Services billed
436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine148$116,168
CombiganBrimonidine Tartrate/Timolol160$72,544
RocklatanNetarsudil Mesylat/Latanoprost137$67,329
Fluorometholone671$64,212
LumiganBimatoprost103$49,286
RhopressaNetarsudil Mesylate116$41,362
Lotemax SmLoteprednol Etabonate104$33,011
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol157$25,209
Prednisolone Acetate179$10,822
Ketorolac Tromethamine236$9,694
Travoprost97$8,539
SimbrinzaBrinzolamide/Brimonidine Tart34$8,121
Loteprednol Etabonate47$6,655
Timolol MaleateTimolol Maleate/Pf25$6,025
Brinzolamide37$5,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$714,765$237,998411 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$16$108,691253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Mocksville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →